UnknownPhase 1

GTA-Glyceryltriacetate for Canavan Disease

Israel5 participantsStarted 2006-01

Plain-language summary

The purpose of this study is to determine whether oral supplementation of glyceryl triacetate improves the clinical prognosis of Canavan Disease.

Age range0 Years – 15 Months

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age below 15 months * Biochemically diagnosed with Canavan Disease Exclusion Criteria: * None

All primary outcome will be evaluated 4 months following the initiation of treatment:

Neurological Status

Brain Imaging: MRI & MRS

NAA Levels in Urine

Ophthalmologic Examination

NCT IDNCT00278707

SponsorSheba Medical Center

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL